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 Abstract 
 Background: Chemotherapies of solid tumors commonly 
include 5-fluorouracil (5-FU). With standard doses of 5-FU, 
substantial inter-patient variability has been observed 
in exposure levels and treatment response. Recently, 
improved outcomes in colorectal cancer patients due to 
pharmacokinetically guided 5-FU dosing were reported. 
We aimed at establishing a rapid and sensitive method for 
monitoring 5-FU plasma levels in cancer patients in our 
routine clinical practice. 
 Methods: Performance of the Saladax My5-FU ™ immuno-
assay was evaluated on the Roche Cobas  ®  Integra 800 ana-
lyzer. Subsequently, 5-FU concentrations of 247 clinical 
plasma samples obtained with this assay were compared 
to the results obtained by liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) and other commonly used 
clinical analyzers (Olympus AU400, Roche Cobas c6000, 
and Thermo Fisher CDx90). 
 Results: The My-FU assay was successfully validated on 
the Cobas Integra 800 analyzer in terms of linearity, preci-
sion, accuracy, recovery, interference, sample carryover, 
and dilution integrity. Method comparison between the 
Cobas Integra 800 and LC-MS/MS revealed a proportional 
bias of 7% towards higher values measured with the 
My5-FU assay. However, when the Cobas Integra 800 was 
compared to three other clinical analyzers in addition to 
LC-MS/MS including 50 samples representing the typical 
clinical range of 5-FU plasma concentrations, only a small 
proportional bias (  ≤  1.6%) and a constant bias below the 
limit of detection was observed. 
 Conclusions: The My5-FU assay demonstrated robust 
and highly comparable performance on different anal-
yzers. Therefore, the assay is suitable for monitoring 5-FU 
plasma levels in routine clinical practice and may con-
tribute to improved efficacy and safety of commonly used 
5-FU-based chemotherapies. 
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 Introduction 
 The anticancer drug 5-fluorouracil (5-FU) is commonly 
used in combination chemotherapies of solid tumors [ 1 ]. 
In general, 5-FU is administered by continuous intrave-
nous infusion, bolus injection or as an oral prodrug for-
mulation (e.g., capecitabine). Substantial inter-individual 
variability in drug exposure and therapy response has 
been observed in the Caucasian population at standard 
5-FU doses [ 2 ,  3 ]. Approximately 10% – 20% of patients 
treated with 5-FU-based regimens develop severe tox-
icities of grade 3 or higher as assessed according to the 
National Cancer Institute Common Terminology Criteria 
for Adverse Events (NCI CTCAE). It has been observed that 
the majority of patients exhibit drug levels outside the 
therapeutic range and that more than 50% of patients do 
not benefit from standard 5-FU therapies [ 1 ]. 
 In the current clinical practice, dosing of 5-FU is com-
monly based on the patient ’ s body surface area (BSA), 
even though it has been shown that BSA is a poor pre-
dictor of systemic drug exposure [ 4 – 6 ]. Several studies 
have reported a relationship between drug exposure and 
response in terms of both efficacy and toxicity [ 5 ,  7 – 9 ]. An 
area under the curve (AUC) of 20 – 25 mg × h/L, that is cal-
culated for 5-FU as plasma concentration (mg/L) at steady 
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state multiplied by infusion time (h), has been established 
as the target exposure range for optimal treatment outcome 
in colorectal cancer [ 10 ]. By adjusting the 5-FU dosing 
based on pharmacokinetic monitoring in patients receiv-
ing 5-FU monotherapy, significantly improved response 
rate and fewer gastrointestinal toxicities were observed 
compared to patients treated with conventional dosing 
of 5-FU [ 10 ]. These findings were recently replicated in a 
cohort of 157 metastatic colorectal cancer patients receiv-
ing either pharmacokinetically guided or conventional 
5-FU dosing in FOLFOX (leucovorin, fluorouracil, oxali-
platin) therapy [ 11 ]. Therapeutic drug monitoring (TDM) 
of 5-FU during infusion therapy may be an effective tool to 
reduce the occurrence of adverse side effects due to drug 
concentration levels above the optimal range, as well as 
to identify under-dosed patients receiving less effective 
treatment. Therefore, 5-FU TDM could improve both safety 
and efficacy of the treatment. 
 Routine testing of drug levels requires an analytical 
method, which is accurate, rapid, and easy to use. Over 
the last 40 years, a variety of methods for 5-FU analysis 
have been developed, with recent reports applying liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) 
[ 12 – 18 ]. Although, LC-MS/MS methods are very sensitive 
and robust, the instrumentation is not yet in standard use 
in routine clinical laboratories. In addition, there is no cer-
tified commercial kit assay currently available for measur-
ing 5-FU plasma levels by LC-MS/MS that can be readily 
used by routine laboratories. However, a nanoparticle 
immunoassay for 5-FU analysis (My5-FU ™ ; Saladax Bio-
medical, Inc., PA, USA) was recently developed and evalu-
ated on the Olympus AU400 analyzer (Beckman Coulter, 
Nyon, Switzerland) [ 19 ,  20 ]. In this study, we evaluated 
the My5-FU assay performance on the Cobas  ®  Integra 800 
analyzer (Roche Diagnostics, Rotkreuz, Switzerland) and 
compared results from clinical plasma samples to those 
obtained by LC-MS/MS and by three other clinical analyz-
ers. Our aim was to establish a rapid and sensitive method 
for monitoring 5-FU plasma levels in cancer patients in 
our routine clinical practice. 
 Materials and methods 
 Samples 
 Clinical samples were collected from 32 gastrointestinal cancer pa-
tients receiving prolonged (48 h) 5-FU infusion therapy at the Can-
tonal Hospital of St. Gallen, Switzerland, according to a study pro-
tocol approved by the local Ethics Committee (EKSG 08/088). All 
study participants provided written informed consent. A total of 197 
samples were taken at several time points during the " rst two cycles 
of chemotherapy. Blood samples were collected in heparinized tubes 
and immediately placed on ice to inhibit dihydropyrimidine dehydro-
genase (DPD) enzyme activity to avoid 5-FU degradation [ 21 ]. Plasma 
was separated within 1 h a$ er blood collection and samples were 
stored at  − 20 ° C until analysis. Plasma samples from healthy volun-
teers were obtained using the same procedure as described above, 
and if needed, pooled and spiked to assess di& erent validation pa-
rameters. In addition, a set of 50 samples (banked samples from pa-
tients on 5-FU-containing regimens) was provided by Saladax Bio-
medical for method comparison. 
 My5-FU assay 
 The My5-FU immunoassay was developed for rapid determination of 
5-FU levels in human plasma [ 19 ]. The assay is based on aggregation 
of nanoparticles that is inversely proportional to the amount of 5-FU 
in the sample, and it can be applied to automated clinical chemistry 
analyzers with photometric detection. The assay reagents, calibra-
tors, and quality control (QC) samples for the study were provided by 
Saladax Biomedical. The calibrator set contained standards at 0, 150, 
300, 600, 1200, and 1800 ng/mL of 5-FU, and the three QC samples 
(low, medium, and high control) contained 5-FU at concentrations of 
225 ng/mL, 450 ng/mL, and 900 ng/mL, respectively. 
 Assay validation on Cobas Integra 800 
 The performance of the My5-FU assay was evaluated on the Cobas 
Integra 800 analyzer. The following validation parameters were as-
sessed: linearity, within-run precision, within-run accuracy, total 
precision, between-day precision, between-day accuracy, recovery, 
interference, sample carryover, and dilution integrity. Prior to each 
run, a calibration and duplicate QC analyses were performed. QC sam-
ples had to be within the speci" cations recommended by the manu-
facturer:  ± 8% for the low QC sample (range 207 – 243 ng/mL),  ± 6% for 
the medium QC sample (range 423 – 477 ng/mL), and  ± 5% for the high 
QC sample (range 855 – 945 ng/mL). 
 Linearity was assessed using " ve replicates of 11 di& erent 5-FU 
concentrations covering the calibration range. Samples for linear-
ity assessment were obtained by diluting plasma spiked at a high 
concentration of 5-FU (1750 ng/mL) with plasma spiked at a low 
concentration (100 ng/mL) as described in the Clinical Laboratory 
Standards Institute (CLSI) Guideline EP6-A [ 22 ]. Linearity was con-
sidered acceptable if the imprecision (coe'  cient of variation, CV) 
at each concentration level was   ≤  15% and the inaccuracy (percent 
bias, %bias) was within  ± 10% for concentrations   ≥  150 ng/mL and 
within  ± 15% for concentrations  < 150 ng/mL. 
 Within-run imprecision (CV) was determined on two separate 
days by analyzing on each day 20 replicates of the low and the me-
dium QC samples and two plasma pools (pooled from " ve healthy 
donors), which were spiked with 5-FU at concentrations of 240 and 
700 ng/mL. Imprecision of   ≤  10% was considered acceptable follo-
wing the manufacturer ’ s recommendation. No speci" cations for 
within-run inaccuracies were stated by the manufacturer. However, 
according to internationally accepted guidelines for bioanalytical 
method validation [ 23 ,  24 ], within-run inaccuracies (%bias) should 
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not exceed 15%. The total imprecision (CV) was determined by ana-
lyzing 40 replicates of each QC sample in " ve days (two replicates/
sample; two samples/run; two runs/day) with a CV speci" cation 
limit of   ≤  15% stated by the manufacturer. Additionally, a between-
day imprecision (CV) over 31 days was evaluated by analyzing one 
replicate of each QC sample per day. If results of the QC replicates 
were outside the speci" cation range, the samples were re-analyzed 
and both replicates included in the between-day imprecision calcu-
lation. All three QC concentration levels over these 31 days had to be 
re-analyzed 14 times, thus, the between-day imprecision is reported 
with a total of 45 replicates per QC sample. Between-day CV of   ≤  15% 
was considered acceptable following the manufacturer ’ s recommen-
dation. Similarly, a between-day inaccuracy (%bias) was evaluated 
applying a speci" cation limit of  ± 15% [ 23 ,  24 ]. 
 Percentage recovery was assessed in 5-FU-free lithium-heparin 
plasma spiked at the following 5-FU concentrations: 250, 500, 1000, 
1250, and 1600 ng/mL. Five replicates per sample were analyzed. 
 The percentage interference for compounds potentially 
 present in plasma, i.e., lipids, bilirubin, protein, and  rheumatoid 
factor, was assessed using the following procedure:  Samples 
for   intra-lipid (mean concentration of 1864 mg/dL), protein 
( human   immunoglobulin G; 12.5 g/dL), and rheumatoid  factor 
(500  units/dL) testing were prepared by adding the respec-
tive interferent or an appropriate control (i.e., saline or plasma) 
to a pooled plasma sample, which was spiked with 1200 ng/mL 
5-FU, following the CLSI Guideline EP7-A2 [ 25 ]. Accordingly, " ve 
 anonymous routine samples with a mean bilirubin concentration 
of 100  µ mol/L were spiked with 1000 ng/mL 5-FU to assess the 
 relative recovery of 5-FU compared to a control sample in presence 
of bilirubin. For interference, a speci" cation limit of  ± 10% was 
 de" ned by the manufacturer. 
 Sample carryover was assessed in one run with randomly dis-
tributed replicates of two calibrator samples with low (n = 11) or high 
(n = 10) 5-FU concentration, 150 or 1800 ng/mL, respectively. Finally, 
the dilution integrity of plasma samples was evaluated up to 10-fold 
using water, zero calibrator standard, and 0.9% sodium chloride so-
lution (B. Braun, Melsungen, Germany). 
 Method comparison 
 For method comparison, 247 human plasma samples were analyzed 
with the My5-FU immunoassay and an LC-MS/MS assay. Of these, 
a set of 50 samples was provided by Saladax Biomedical, whereas 
the rest of the samples were from cancer patients treated with 5-FU-
based regimens at the Cantonal Hospital of St. Gallen. Samples con-
taining 5-FU concentrations above the linear calibration range of the 
My5-FU assay were diluted up to 10-fold with water before analysis. 
Most of the LC-MS/MS analyses were performed as described earlier 
on a QTRAP  ®  4000 linear ion trap quadrupole mass spectrometer (AB 
SCIEX, Darmstadt, Germany) [ 12 ]. A subset of samples was analyzed 
applying the same method with " ne adjustments to a newer version 
of this LC-MS/MS system, i.e., a QTRAP 5500 (AB SCIEX). The speci" c 
MS/MS parameters can be requested from the authors. The results 
obtained on Cobas Integra 800 analyzer and LC-MS/MS for the sub-
set of 50 samples were also compared to results obtained using the 
My5-FU assay on three other automated clinical analyzers, namely 
Olympus AU400, Roche Cobas c6000, and Thermo Fisher CDx90 
(data provided by Saladax Biomedical). 
 For each method comparison (method 1 vs. method 2), results 
were compared using the Passing-Bablok regression analysis gen-
erating a linear equation with calculated values for intercept and 
slope [ 26 ]. The intercept value represents a measure for potential 
systematic di& erences between methods. If the 95% con" dence in-
terval (CI) of the intercept contains zero, methods show no evidence 
for a systematic di& erence. However, if the 95% CI does not include 
zero, a constant bias between the methods is present. Accordingly, 
if the 95% CI of the slope does not include one, a proportional bias 
between the methods is detected. 
 To test the validity of the linear model, the Passing-Bablok 
analysis includes a cumulative sum (Cusum) linearity test [ 26 ]. The 
threshold for rejecting the null hypothesis of a linear relationship 
was set to  α = 10%. Correlation analysis was additionally performed 
for all method comparisons obtaining a squared Pearson correlation 
coe'  cient  ( )2 .PearsonR  
 The degree of agreement between methods was further evalu-
ated by using the Bland-Altman analysis, plotting the mean percent 
di& erence against the average of both methods [ 27 ]. 
 The method comparison analyses were performed with the 
Analyse-it  ®  v2.20 so$ ware add in for Microso$   ®  Excel ™ (Microso$  
Corporation, Redmond, WA, USA). 
 Results 
 Assay validation on Cobas Integra 800 
 The assay was found to be linear over the entire concen-
tration range of 5-FU (100 – 1750 ng/mL). Linearity was 
described with the following linear regression equa-
tion: y = 1.09 × x – 25.9. The CV of all concentration levels 
was   ≤  3.7%, and the %bias was   ≤  7.4%. 
 The defined specification criteria were met for impre-
cision and inaccuracy. Within-run imprecision was tested 
by analyzing 20 replicates of the low and the medium 
QC sample and two pooled plasma samples spiked with 
5-FU on two separate days. For QC samples, the within-
run CV ranged from 0.95% to 3.9% and for pooled plasma 
samples from 0.65% to 2.2% ( Table 1 ), being within the 
acceptable specification limit (  ≤  10%). The within-run 
%bias for QC samples ranged from 4.8% to 7.4% and for 
pooled samples from 2.2% to 8.6%, being also within the 
specification criteria ( ± 15%). Total CV (n = 40) for the low, 
the medium, and the high QC concentration levels were 
3.5%, 2.7%, and 1.4% (specification limit:   ≤  15%), respec-
tively. Similarly, between-day CVs (n = 45) of 5.6%, 3.5%, 
and 2.1% (specification limit:   ≤  15%) and %biases of 3.7%, 
3.8%, and 2.4% (specification limit:  ± 15%) were obtained 
for the respective QC samples. 
 The percentage recovery for different 5-FU concentra-
tions ranged from 99% to 105% ( Table 2 ), and was thus 
within the acceptable range (96% – 108%) given by the 
manufacturer. 
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 Low interference by bilirubin ( − 5%), total protein 
(4%), and rheumatoid factor ( − 2%) was observed. 
However, intra-lipids showed an interference of 11%. 
 Sample carryover was evaluated using randomly dis-
tributed replicates (n = 21) of low and high 5-FU calibra-
tor samples (150 and 1800 ng/mL, respectively). Since a 
CV of 2.6% and %bias of 7.4% was observed for the low 
concentration sample, the preceding high concentration 
sample had no influence on the low sample indicating the 
absence of any carryover effects. 
 Finally, a 10-fold dilution of three clinical plasma 
samples with water, zero calibrator standard or 0.9% 
sodium chloride solution yielded an imprecision of   ≤  10%. 
 Method comparison 
 Of the 247 clinical samples analyzed for the method com-
parison, 107 (43%) contained 5-FU concentrations above 
 Table 1   Within-run imprecision and inaccuracy of quality control and two plasma pool samples spiked with 5-FU. 
 Sample type  Replicates  Nominal 5-FU 
concentration, ng/mL 
 Mean 5-FU 
concentration, ng/mL 
 Standard 
deviation (SD) 
 Imprecision 
(CV), % 
 Inaccuracy 
(%bias) 
 QC, low       
   Day 1  20  225  236  8.62  3.7  4.8 
   Day 2  20  225  239  9.33  3.9  6.2 
   Day 1 and 2  40  225  237  9.01  3.8  5.5 
 QC, medium       
   Day 1  20  450  479  7.78  1.6  6.5 
   Day 2  20  450  483  4.57  0.95  7.4 
   Day 1 and 2  40  450  481  6.68  1.4  6.9 
 Plasma pool 1       
   Day 1  20  240  255  5.65  2.2  6.2 
   Day 2  20  240  261  3.57  1.4  8.6 
   Day 1 and 2  40  240  258  5.51  2.1  7.4 
 Plasma pool 2       
   Day 1  20  700  715  6.41  0.90  2.2 
   Day 2  20  700  734  4.79  0.65  4.9 
   Day 1 and 2  40  700  725  11.1  1.5  3.5 
 CV, coefficient of variation; QC, quality control. 
 Table 2   My5-FU assay recovery of 5-FU in lithium-heparin plasma at 
five different concentrations (n = 5). 
 Parameters  1  2  3  4  5 
 Nominal 5-FU concentration, ng/mL  250  500  1000  1250  1600 
 Mean 5-FU concentration, ng/mL  252  507  992  1309  1597 
 Standard deviation (SD)  3.0  3.8  6.1  11  18 
 Recovery, %  101  101  99.2  105  99.8 
 Imprecision (CV), %  1.2  0.76  0.62  0.83  1.1 
 Inaccuracy (%bias)  0.80  1.3  − 0.84  4.8  − 0.21 
 CV, coefficient of variation. 
the linear calibration range ( > 1800 ng/mL) of the My5-FU 
assay requiring up to 10-fold dilution. The 5-FU concen-
trations determined by LC-MS/MS showed a range from 
102 to 18590 ng/mL with a median concentration of 1270 
ng/mL. Similarly, the 5-FU concentrations obtained with 
the My5-FU assay ranged from 93 to 17881 ng/mL with a 
median concentration of 1342 ng/mL. 
 All method comparison statistics are shown in 
 Table  3 . The comparison between the My5-FU assay 
on the Cobas Integra 800 analyzer and the LC-MS/MS 
method yielded a  2PearsonR  of 0.987. The Passing-Bablok 
analysis of this comparison is shown in  Figure 1 . A linear 
equation of Cobas Integra 800 (ng/mL) = 1.08 × LC-MS/
MS (ng/mL) – 3.96 (95% CI slope 1.06 – 1.09; 95% CI inter-
cept  – 14.5 – 11.4) was obtained ( Table 3 ). The CI of the 
slope indicated a proportional bias of 8% higher values 
for the Cobas Integra 800 as compared to the LC-MS/
MS method. Accordingly, the Bland-Altman method 
revealed a similar proportional bias of 7% between the 
two methods ( Figure 2 ). 
 Method comparison estimates between the other 
clinical analyzers and the Cobas Integra 800 are listed in 
 Table 3 . The performance of the My5-FU assay was com-
parable between the different instruments all showing a 
 2PearsonR  of   ≥  0.993. They all, however, revealed a similar 
proportional bias with slightly higher values being 
obtained with the Cobas Integra 800 analyzer. In addition, 
a constant bias below the limit of detection ( < 52 ng/mL) 
was observed between Cobas Integra 800 and all other 
clinical analyzers. 
!eeerrreeeiiitttgggeeesssttteeellllllttt      vvvooonnn      |||      UUUnnniiivvveeerrrsssiiitttaaaeeetttsssbbbiiibbbllliiiooottthhheeekkk      !eeerrrnnn
AAAnnngggeeemmmeeellldddeeettt      |||      111333000...999222...999...555555
HHHeeerrruuunnnttteeerrrgggeeelllaaadddeeennn      aaammm      |||      111999...000222...111333      111777:::000000
B ü chel et al.: My5-FU ™ assay performance on Cobas ® Integra 800      5
 Discussion 
 The My5-FU assay was successfully established on the 
Cobas Integra 800 analyzer and results from the analy-
sis of 247 clinical samples showed good correlation with 
LC-MS/MS. Compared to the previously published valida-
tion data on Olympus AU400 analyzer [ 20 ], we report very 
similar imprecision characteristics: within-run CV of 3.9% 
vs. 2%, and a total CV of 3.5% vs. 3.9%. Overall, the assay 
validation criteria were met for linearity, precision, accu-
racy, recovery, sample carryover, and dilution integrity. 
However, an interference of 11% was observed for intra-
lipids. This could be explained by a freezing effect, since 
the interference was gradually increasing while the 
sample was re-frozen and thawed between the analyses. 
Although the assay has been validated for three freeze-
thaw cycles, it is recommended to keep plasma samples 
at 4 ° C until analysis, and freeze sample aliquots for longer 
storage. Furthermore, the preanalytical handling of the 
samples may have a great influence on the quality of the 
results. Most importantly, the residual DPD enzyme acti-
vity in the sample needs to be inhibited immediately after 
 Table 3   Method comparison statistics. 
 Method 1  Method 2  n  Concentration range 
of method 1, ng/mL 
 Slope a 
 (95% CI) 
 Intercept a 
 (95% CI) 
 Cusum 
p-value b 
 %bias c 
 (95% CI)  
2
PearsonR  
 LC-MS/MS  Integra 800  247  102 – 18 590  1.08 (1.06 – 1.09)  − 3.96 ( − 14.5 – 11.4)  > 0.1  7.0 (5.5 – 8.5)  0.987 
 Integra 800  LC-MS/MS  50  93 – 1581  0.97 (0.95 – 0.99)  12.0 ( − 2.20 – 19.0)  > 0.1  − 1.4 ( − 2.6 – − 0.2)  0.996 
 Integra 800  AU400  50  93 – 1581  0.96 (0.95 – 0.97)  18.1 (12.6 – 26.5)  > 0.1  0.2 ( − 1.5 – 1.9)  0.999 
 Integra 800  CD × 90  50  93 – 1581  0.94 (0.93 – 0.95)  32.3 (23.4 – 43.5)  > 0.1  0.6 ( − 1.1 – 2.3)  0.998 
 Integra 800  c6000  45  93 – 1581  0.96 (0.95 – 0.99)  19.8 (9.90 – 32.2)  > 0.1  1.6 (0.1 – 3.1)  0.993 
 LC-MS/MS  Integra 800  50  102 – 1560  1.03 (1.01 – 1.05)  − 12.3 ( − 19.9 – 2.22)  > 0.1  1.4 (0.2 – 2.6)  0.996 
 LC-MS/MS  AU400  50  102 – 1560  0.99 (0.97 – 1.01)  11.2 ( − 2.75 – 26.7)  > 0.1  1.6 ( − 0.1 – 3.2)  0.995 
 LC-MS/MS  CD × 90  50  102 – 1560  0.97 (0.95 – 0.99)  21.6 (6.95 – 38.9)  > 0.1  2.0 (0.3 – 3.6)  0.992 
 LC-MS/MS  c6000  45  102 – 1560  0.99 (0.97 – 1.02)  10.8 ( − 3.63 – 33.7)  > 0.1  2.7 (1.1 – 4.2)  0.991 
 a Passing-Bablok regression parameter;  b Cusum linearity test of Passing-Bablok fit;  c Percentage of the mean difference according to Bland 
Altman. CI, confidence interval. 
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 Figure 1   Passing-Bablok analysis of the Cobas Integra 800 compared to LC-MS/MS (n = 247). 
 The black full line is the regression line and the two dashed lines show the 95% CI of its slope. The grey full line is the identity line 
(slope = 1). 
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blood drawing as it will lead to artificially lowered 5-FU 
plasma concentrations, and thus, to the risk of missing 
patients at high risk of toxicity due to elevated steady-state 
5-FU levels. The inhibition of the residual enzyme activity 
may be achieved by immediate cooling of the sample on 
ice before plasma separation, or by adding a commercially 
available stabilizer (provided by Saladax Biomedical) to 
the sample. 
 The Passing-Bablok and Bland-Altman analyses 
revealed a proportional bias towards higher values using 
the My5-FU assay on the Cobas Integra 800 analyzer 
compared to LC-MS/MS. Accordingly, slightly higher con-
centrations of 5-FU compared to the nominal concentra-
tions were generally observed for QC and spiked plasma 
samples using the My5-FU assay ( Table 1 ). However, the 
precision and the accuracy were within the acceptable 
range and a positive bias of 7% would not lead to an unin-
tentional under-dosing of a patient who is on the optimal 
AUC target level (22.5 mg × h/L  ± 11.1%). The apparent lack 
of such a proportional bias in the comparisons between 
the My5-FU assay on other clinical chemistry analyzers 
and the LC-MS/MS assay may be largely explained by the 
more than 10-fold extended range of concentration values 
and the five-fold larger sample size that were included in 
the comparison of the Cobas Integra 800 and LC-MS/MS 
(93 – 18590 ng/mL vs. 93 – 1581 ng/mL;  Table 3 ). Indeed, the 
proportional bias in the comparison of the Cobas Integra 
800 analyzer and LC-MS/MS is strongly reduced to 1.4% 
if the same smaller set of samples is compared ( Table 3 ). 
 Since the standard infusional regimens, such as 
FOLFOX, use an infusion time of 48 h, the optimal steady-
state levels are low (i.e., 417 – 521 ng/mL with the target 
AUC of 20 – 25 mg × h/L). Thus, the data included in the 
additional method comparison series based on a subset 
of samples (n = 50) analyzed by using the Cobas Integra 
800 and three other clinical chemistry analyzers in addi-
tion to LC-MS/MS, were within a clinical range of plasma 
concentrations. Our results suggest that the performance 
of the My5-FU assay on the different analyzers is highly 
comparable ( Table 3 ). Compared to the LC-MS/MS assay, 
only a small proportional bias and a constant bias below 
the limit of detection ( < 52 ng/mL) were observed. 
 In conclusion, we have demonstrated that the evalu-
ated method is reliable for routine monitoring of 5-FU 
plasma levels in cancer patients. We confirmed the assay 
robustness on different analyzers commonly used in 
clinical laboratories. Steady-state plasma concentration 
levels of 5-FU are rapidly provided for physicians and the 
patient ’ s treatment can be adjusted if necessary. This is 
possible because standard 5-FU therapy regimen cycles 
are biweekly, and delayed toxicity symptoms may occur 
up to several days or weeks after the first cycle of therapy. 
Monitoring 5-FU plasma levels may provide an effective 
approach to improve efficacy and safety of commonly 
used 5-FU-based therapies in cancer patients. 
 Acknowledgments:  The My5-FU assay reagents, calibra-
tors, pooled plasma samples for validation, 50 clinical 
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 Figure 2   Bland-Altman plot of the Cobas Integra 800 compared to LC-MS/MS. 
 The grey full line represents the identity line (i.e., full agreement between both methods), whereas the black full line indicates the bias 
between the methods. The two dashed lines show the 95% CI. 
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